Alternative Vismodegib Dosing Regimen for Patients with Basal Cell Carcinoma

Main Article Content

Timothy Jay Orlowski
Callie Hill
Natalie Garcia
Victoria Jiminez
Carlton Phillips

Keywords

Pharmacology, Vismodegib, Basal cell carcinoma, Skin cancer

References

1. Proctor AE, Thompson LA, O'Bryant CL. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma. Ann Pharmacother. 2014;48(1):99-106.

2. Sekulic A, Migden MR, Lewis K, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72(6):1021-6.e8.

3. Dréno B, Kunstfeld R, Hauschild A, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18(3):404-412.

4. Villani A, Costa C, Fabbrocini G, et al. Drug holiday regimen for vismodegib treatment in patients with multiple primary basal cell carcinomas. Dermatol Ther. 2020;33(4):e13707.

5. Valenzuela-Oñate CA, Magdaleno-Tapial J, Garcia-Legaz Martínez M, et al. Drug holiday approach for Vismodegib treatment in patients with nevoid basal cell carcinoma syndrome: Three cases from real clinical practice. Dermatol Ther. 2020;33(4):e13540.

6. Wong C, Poblete-Lopez C, Vidimos A. Comparison of daily dosing versus Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: A retrospective case series. J Am Acad Dermatol. 2020;82(6):1539-1542.